J Periodontol: Omega-3 PUFA and aspirin can be used as complementary treatments for periodontitis and periodontry in patients with type 2 diabetes

Some scholars have suggested that supplementation with omega-3 polyunsaturated fatty acids (omega-3 PUFA) and low-dose aspirin (ASA) as host regulatory systems for controlling chronic inflammatory diseases is lacking in high-quality clinical studies.
recent study, published in J Periodontol, explores the clinical and immunological effects of oral omega-3 PUFA and ASA as aids in treating periodontitis patients with type 2 diabetes.
study included 75 patients as subjects.
were randomly divided into 3 groups, receiving placebo and periodont (CG), respectively, and receiving omega-3 PUFA-ASA (3 g fish oil/d-100 mg ASA/d, 2 months) (Test group (TG) 1), or before the ticks are created, receive the omega-3 PUFA-ASA (3 g fish oil/d-100 mg ASA/d, 2 months) (TG2).
as well as cell phone periodont parameters and GCF for 3 and 6 months after treatment.
results showed that 10 patients (40%) in TG1 and 9 patients (36%) in TG2 reached the clinical end of treatment (visit depth ≥5mm site ≤4), while only 4 out of CG (16%).
increase in clinical attachment levels at both depth and depth of TG1 visits.
IFN-γ (IL)-8 in two trial groups decreased over time.
the IL-6 level of TG1 is low.
HbA1c level of TG1 is reduced.
above, the results show that periodont-scratching assisted omega-3 and ASA have clinical and immunological benefits for the treatment of periodontitis in patients with type 2 diabetes.